RCT in 120 patients with new psoriatic arthritis: early secukinumab treat-to-target did not improve ACR50 at 6 months vs standard step-up care (42% vs 35%; RR 1.19, p=0.45). Serious adverse events: 10% vs 8%.
RCTn = 120
Koc et al. Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies